# Cochrane

# Trusted evidence.

# Informed decisions.

# Library

# Better health.

# Cochrane Database of Systematic Reviews

# Sarbagili Shabat 2022

# Study characteristics

# Methods

Multicenter, single-blind RCT conducted in Israel and Italy

# Participants

# Inclusion criteria

- Ages 18–70 years (inclusive)
- Established diagnosis of UC, confined to the large intestine with rectosigmoid involvement for ≥ 3 months
- Mild-to-moderate active disease, SCCAI score ≥ 5 and < 10 with Endoscopic subscore ≥ 2
- Refractory to mesalamine for 6 weeks, steroids > 14 days, or immunomodulator therapy for 12 weeks, biologics for ≥ 12 weeks
- No use or stable use of medical cannabis for 2 weeks
- Informed consent

# Exclusion criteria

- Acute severe UC in past 3 months
- Start of new biologic therapy in previous 12 weeks, FMT in last 6 months
- Evidence of Clostridioides difficile infection, any confirmed current infection such as cytomegalovirus, positive stool culture, or parasite
- Current extra-intestinal manifestation of UC such as active arthritis or primary sclerosing cholangitis
- Immune deficiency (other than drug-induced)
- Current use of calcineurin inhibitor
- Pregnancy
- Suspected toxic megacolon, guarding on palpation, or signs of peritoneal inflammation; presence of a pouch or pouchitis
- Other IBD-unrelated disease such as autoimmune disorders, renal failure, fever (< 38 °C) or current infection (UTI, strep throat, pneumonia, etc.)
- Prior or current neoplasia, active malignant disease or prior malignancy in past 5 years (excluding skin basal cell carcinoma)
- Inability or reluctance to use enema
- Anticipation of antibiotic use within the study period (such as for elective surgery or dental treatment)
- Participation in another clinical interventional trial

# Interventions

# Experimental arm

- FMT by colonoscopy on day 1 + 60 mL enemas on days 2 and 14 from the same donor, with dietary pre-conditioning of donor for 14 days and dietary treatment of patient for 12 weeks

# Control arm 1

- FMT by colonoscopy on day 1 + 60 mL enemas on days 2 and 14 from the same donor, without dietary conditioning

# Control arm 2

- Dietary treatment of participant for 12 weeks without FMT

# Outcomes

# Primary outcome

- Clinical remission at week 8, determined by SCCAI score < 3

# Secondary outcomes

- Improvement in SCCAI score for each group at weeks 8 and 12
- Mayo Endoscopic score < 2 (for participants undergoing sigmoidoscopy) at week 8

Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.